Disease · GO_0006954

inflammatory response

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. inflammatory response. Diseases, record GO_0006954. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/GO_0006954

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: inflammatory response; Open Targets
Open Targets ID: GO_0006954; Open Targets
Other names: INFLAMM, Inflammations, inflammation; Open Targets
MeSH: D007249; MeSH
NCI Thesaurus: C20151; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 14 drugs, from ClinicalTrials.gov; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALBUMIN HUMAN	CHEMBL1201451	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROXYETHYL STARCH 130/0.4	CHEMBL2108701		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FISH OIL	CHEMBL3833369		Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
SOYBEAN OIL	CHEMBL1201485		Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
SEVOFLURANE	CHEMBL1200694	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02192502	Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients	Phase 3	149	2023-02-14	Postoperative Kidney Injury	ALBUMIN HUMAN, HYDROXYETHYL STARCH 130/0.4	Its record names the disease	ClinicalTrials.gov
NCT01377623	Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion	Not applicable	66	2016-12-14	Spinal Stenosis, Inflammation	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov
NCT04990752	Effects of Ulinastatin on Inflammatory Response During ECMO Support		144		ECMO, Inflammatory Response	ULINASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02672345	Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB		100		Inflammatory Response	SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT01547455	Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery	Not applicable	96		Acute Kidney Injury	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02056717	Use of Dexamethasone in Uterine Artery Embolization	Not applicable	64		Uterine Myoma, Adenomyosis	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT03163238	Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery	Phase 2	60		Cardiac Surgical Procedures	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov
NCT05289349	Propofol or Sevoflurane Anesthesia in Egyptian Patients	Not applicable	44		Anesthesia	PROPOFOL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT02612480	Ticagrelor in Human Endotoxemia Response to Human Endotoxemia	Not applicable	40		Endotoxemia	CLOPIDOGREL, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT00336908	Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery	Phase 2/3	32		Inflammation, Cardiac Surgical Procedures	FISH OIL, SOYBEAN OIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
HES 130/0.4 (Voluven) vs Human Albumin 5%: deaths from any cause	0 of 69	2 of 72	141	NCT02192502	Trial comparisons
HES 130/0.4 (Voluven) vs Human Albumin 5%: serious adverse events	17 of 69	12 of 72	141	NCT02192502	Trial comparisons
Dexmedetomidine Group (PFD) vs Placebo Group (PFS): serious adverse events	0 of 26	0 of 28	54	NCT01377623	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22824921	RESULT	1	PubMed
34406128	DERIVED	1	PubMed
33744114	DERIVED	1	PubMed
33407763	DERIVED	1	PubMed
32072617	DERIVED	1	PubMed
22136963	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/GO_0006954

GET https://conductscience.org/api/diseases/v1/GO_0006954/targets?page=2

API reference For AI assistants